Daiichi Sankyo's edoxaban blood thinner hits main goals in trial

11/19/2013 | Reuters

Daiichi Sankyo's edoxaban was at least as efficient as warfarin in the prevention of stroke or systemic embolism and was associated with lower rates of bleeding and death, a late-stage study showed. The trial tested 60 milligram and 30 mg doses of edoxaban against warfarin, and the higher dosage reduced stroke and blood clots by 21% and overall major bleeding by 20%, compared with warfarin. Daiichi Sankyo intends to submit the drug for FDA review in the first quarter of next year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ